https://scholars.lib.ntu.edu.tw/handle/123456789/512397
標題: | Clinical impact of using fluoroquinolone with low antimycobacterial activity on treatment delay in tuberculosis: Hospital-based and population-based cohort study | 作者: | MENG-RUI LEE Lee C.-H. JANN-YUAN WANG Lee S.-W. JEN-CHANG KO LI-NA LEE |
公開日期: | 2020 | 出版社: | Elsevier B.V. | 卷: | 119 | 期: | 1P2 | 起(迄)頁: | 367-376 | 來源出版物: | Journal of the Formosan Medical Association | 摘要: | Background/Purpose: Little remains known regarding whether newer FQ with less anti-mycobacterial activity (gemifloxacin) would reduce treatment delay. Methods: We identified one hospital-based cohort (HBC) and one population-based cohort (PBC) including patients receiving amoxicillin/clavulanate acid (Beta-lactam), gemifloxacin (Gemi), and fluoroquinolones other than gemifloxacin (Non-Gemi FQ) prior to TB treatment. Results: A total of 201 patients in the HBC and 3544 patients in the PBC were recruited. After 1:1 propensity score matching, TB treatment delay was statistically insignificant between Beta-lactam, Gemi group, and Non-Gemi FQ group in HBC (Beta-lactam vs Gemi: 22.3 ± 21.4 d vs 28.6 ± 27.9 d, p = 0.292; Beta-lactam vs Non-Gemi FQ: 33.3 ± 26.5 d vs 50.3 ± 47.3 d, p = 0.135) and PBC (Beta-lactam vs Gemi: 26.4 ± 29.1 vs 25.0 ± 28.1, p = 0.638; Beta-lactam vs Non-Gemi FQ: 29.4 ± 36.0 d vs 32.7 ± 35.0 d, p = 0.124, Non-Gemi FQ vs Gemi: 28.4 ± 33.0 d vs 25.0 ± 28.1 d, p = 0.29). Conclusion: While limited by relatively low case number, our study showed that use of gemifloxacin neither results in nor reduces delay in TB treatment. The issue of FQ use on TB treatment delay was also not observed in our study. Early survey and maintaining high clinical alertness remains the key to reducing TB treatment delay. ? 2019 Formosan Medical Association |
URI: | https://www.scopus.com/inward/record.uri?eid=2-s2.0-85068047769&doi=10.1016%2fj.jfma.2019.06.008&partnerID=40&md5=3d238da4795798c713397132c631b9ee https://scholars.lib.ntu.edu.tw/handle/123456789/512397 |
ISSN: | 0929-6646 | DOI: | 10.1016/j.jfma.2019.06.008 | SDG/關鍵字: | amoxicillin plus clavulanic acid; ciprofloxacin; gemifloxacin; levofloxacin; moxifloxacin; ofloxacin; quinolone derivative; antiinfective agent; gemifloxacin; quinolone derivative; tuberculostatic agent; adult; antibiotic therapy; Article; cohort analysis; comorbidity; comparative study; controlled study; female; hospital based case control study; human; ICD-9-CM; major clinical study; male; middle aged; propensity score; therapy delay; thorax radiography; tuberculosis; aged; factual database; hospital; Taiwan; time to treatment; tuberculosis; very elderly; Adult; Aged; Aged, 80 and over; Anti-Bacterial Agents; Antitubercular Agents; Cohort Studies; Databases, Factual; Female; Fluoroquinolones; Gemifloxacin; Hospitals; Humans; Male; Middle Aged; Propensity Score; Taiwan; Time-to-Treatment; Tuberculosis |
顯示於: | 醫學系 |
在 IR 系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。